FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308379957> ?p ?o ?g. }

• W4308379957 abstract "<h3>Background</h3> Liquid biopsy (LBx) based low pass whole genome sequencing (LP-WGS) derived blood copy number burden (bCNB) with defined clinical cut-offs provides a genome-wide overview for monitoring molecular reponse. LBx DNA methylation analysis promises sensitivity for monitoring treatment response and possibly provides tissue of origin (TOO) insights. The potential clinical utility of the multi-faceted approaches to monitor molecular response using bCNB and DNA methylation in the metastatic colorectal cancer (mCRC) palliative treatment setting were investigated. <h3>Methods</h3> Seventy longitudinal (baseline, on-treatment, and end of treatment (EOT)) plasma samples were collected from 14 mCRC patients treated with chemotherapy (CTx) alone or in combination with one or more targeted agents and PD-L1 blockade (figure 1). bCNB and DNA methylation were analyzed at all timepoints, respectively. bCNB is calculated based on the genome-wide copy number abnormalities, normalized by the LP-WGS profiles from healthy donors. Furthermore, a clinical applicable cut-off can be defined for molecular response monitoring. DNA methylation provides whole-genome methylation profiles using input amounts as low as 1 ng. Personalized MRD which uses patient-specific mutation and fixed panels, was utilized to generate MRD data for the 11 baselines, time points and EOT samples. <h3>Results</h3> Using bCNB, eight patients treated with CTx in combination with different therapies such as targeted agents and PD-L1 blockade showed a consistent reduction in tumor burden compared to baseline, with post-treatment bCNB values below the cut-off of 5.2 (log2) derived from healthy donors (figure 2). DNA Methylation determined TOO, exemplified by the preliminary data detected the enrichment of SMAD4-associated hypermethylated DNA fragments in a patient with metastasis. A cut-off of 9.5 (log2) was defined based on abnormally methylated fragments, which correlated with bCNB (R²=0.83; figure 2). Additionally, indication specific tiered cut-offs for molecular responses can be defined. Tumor fraction estimates using Personalized MRD showed a correspondence with both bCNB (patient-wise correlation, Pearson r=0.87) and abnormal DNA Methylation cut-offs (patient-wise correlation, Pearson r = 0.82) for patients with matching data points, respectively. Conclusions bCNB is a feasible approach for assessing molecular response with cut-off determination, and its low cfDNA input requirement enables clinical utilities. Preliminary data supported that DNA methylation assay detected TOO and demonstrated potential clinically applicable cut-off definitions. bCNB, DNA methylation and Personalized MRD demonstrated concordance and provided a comprehensive suite of solutions for molecular response and MRD monitoring. Collectively, the holistic LBx approaches with clinical applicable cut-off definition would possibly facilitate the selection of patient-centric tailored treatments. <h3>Ethics Approval</h3> The study protocol was in accordance with the tenets of the Declaration of Helsinki. Commercial samples used in this study were procured from Indivumed GmbH following protocols approved by the local Institutional Review Board (IRB) committee. Informed consent forms were obtained from all the human subjects in this study. <h3>Consent</h3> Written informed consent was obtained from the patient for publication of the abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal." @default.
• W4308379957 created "2022-11-11" @default.
• W4308379957 creator A5005708372 @default.
• W4308379957 creator A5010408125 @default.
• W4308379957 creator A5075706799 @default.
• W4308379957 creator A5086778001 @default.
• W4308379957 creator A5091090794 @default.
• W4308379957 date "2022-11-01" @default.
• W4308379957 modified "2023-09-26" @default.
• W4308379957 title "164 Evaluation of liquid biopsy-based plasma copy number burden, DNA methylation and personalized minimal residual disease approach for monitoring molecular response to different drug regimens in metastatic colorectal cancer patient" @default.
• W4308379957 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0164" @default.
• W4308379957 hasPublicationYear "2022" @default.
• W4308379957 type Work @default.
• W4308379957 citedByCount "0" @default.
• W4308379957 crossrefType "proceedings-article" @default.
• W4308379957 hasAuthorship W4308379957A5005708372 @default.
• W4308379957 hasAuthorship W4308379957A5010408125 @default.
• W4308379957 hasAuthorship W4308379957A5075706799 @default.
• W4308379957 hasAuthorship W4308379957A5086778001 @default.
• W4308379957 hasAuthorship W4308379957A5091090794 @default.
• W4308379957 hasBestOaLocation W43083799571 @default.
• W4308379957 hasConcept C104317684 @default.
• W4308379957 hasConcept C120821319 @default.
• W4308379957 hasConcept C121608353 @default.
• W4308379957 hasConcept C126322002 @default.
• W4308379957 hasConcept C141231307 @default.
• W4308379957 hasConcept C143998085 @default.
• W4308379957 hasConcept C150194340 @default.
• W4308379957 hasConcept C190727270 @default.
• W4308379957 hasConcept C2778461978 @default.
• W4308379957 hasConcept C2779529041 @default.
• W4308379957 hasConcept C2779823535 @default.
• W4308379957 hasConcept C33288867 @default.
• W4308379957 hasConcept C502942594 @default.
• W4308379957 hasConcept C526805850 @default.
• W4308379957 hasConcept C54355233 @default.
• W4308379957 hasConcept C552990157 @default.
• W4308379957 hasConcept C71924100 @default.
• W4308379957 hasConcept C86803240 @default.
• W4308379957 hasConceptScore W4308379957C104317684 @default.
• W4308379957 hasConceptScore W4308379957C120821319 @default.
• W4308379957 hasConceptScore W4308379957C121608353 @default.
• W4308379957 hasConceptScore W4308379957C126322002 @default.
• W4308379957 hasConceptScore W4308379957C141231307 @default.
• W4308379957 hasConceptScore W4308379957C143998085 @default.
• W4308379957 hasConceptScore W4308379957C150194340 @default.
• W4308379957 hasConceptScore W4308379957C190727270 @default.
• W4308379957 hasConceptScore W4308379957C2778461978 @default.
• W4308379957 hasConceptScore W4308379957C2779529041 @default.
• W4308379957 hasConceptScore W4308379957C2779823535 @default.
• W4308379957 hasConceptScore W4308379957C33288867 @default.
• W4308379957 hasConceptScore W4308379957C502942594 @default.
• W4308379957 hasConceptScore W4308379957C526805850 @default.
• W4308379957 hasConceptScore W4308379957C54355233 @default.
• W4308379957 hasConceptScore W4308379957C552990157 @default.
• W4308379957 hasConceptScore W4308379957C71924100 @default.
• W4308379957 hasConceptScore W4308379957C86803240 @default.
• W4308379957 hasLocation W43083799571 @default.
• W4308379957 hasOpenAccess W4308379957 @default.
• W4308379957 hasPrimaryLocation W43083799571 @default.
• W4308379957 hasRelatedWork W1998770206 @default.
• W4308379957 hasRelatedWork W2109712655 @default.
• W4308379957 hasRelatedWork W2341114501 @default.
• W4308379957 hasRelatedWork W2486351012 @default.
• W4308379957 hasRelatedWork W2612908078 @default.
• W4308379957 hasRelatedWork W2972416174 @default.
• W4308379957 hasRelatedWork W2983668961 @default.
• W4308379957 hasRelatedWork W3049509200 @default.
• W4308379957 hasRelatedWork W4311504196 @default.
• W4308379957 hasRelatedWork W4367319693 @default.
• W4308379957 isParatext "false" @default.
• W4308379957 isRetracted "false" @default.
• W4308379957 workType "article" @default.